Alaina M Jaster1,2, Harrison Elder2, Samuel A Marsh2, Mario de la Fuente Revenga1,3, S Stevens Negus4, Javier González-Maeso5. 1. Department of Physiology & Biophysics, Virginia Commonwealth University School of Medicine, Richmond, VA, 23298, USA. 2. Department of Pharmacology & Toxicology, Virginia Commonwealth University School of Medicine, Richmond, VA, 23298, USA. 3. Virginia Institute of Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, VA, 23298, USA. 4. Department of Pharmacology & Toxicology, Virginia Commonwealth University School of Medicine, Richmond, VA, 23298, USA. sidney.negus@vcuhealth.org. 5. Department of Physiology & Biophysics, Virginia Commonwealth University School of Medicine, Richmond, VA, 23298, USA. javier.maeso@vcuhealth.org.
Abstract
BACKGROUND: Clinical studies suggest that psychedelics exert robust therapeutic benefits in a number of psychiatric conditions including substance use disorder. Preclinical studies focused on safety and efficacy of these compounds are necessary to determine the full range of psychedelics' effects. OBJECTIVES: The present study explores the behavioral pharmacology of structurally distinct psychedelics in paradigms associated with serotonin 2A receptor (5-HT2AR) activation and behavioral disruption in two rodent models. Utilizing the selective 5-HT2AR antagonist volinanserin, we aimed to provide further pharmacological assessment of psychedelic effects in rodents. METHODS: We compared volinanserin (0.0001-0.1 mg/kg) antagonism of the phenethylamine 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI, 1.0 mg/kg) and the ergoline lysergic acid diethylamide (LSD, 0.32 mg/kg) in preclinical assays predictive of hallucinations (head-twitch response or HTR in mice) and behavioral disruption (intracranial self-stimulation or ICSS in rats). Volinanserin antagonism of the phenethylamine mescaline, the tryptamine psilocybin, and the k-opioid receptor agonist salvinorin A was also evaluated in the rat ICSS assay. RESULTS: Volinanserin had similar potency, effectiveness, and time-course to attenuate DOI-induced HTR in mice and ICSS depression in rats. Volinanserin completely blocked LSD-induced HTR in mice, but not LSD-induced ICSS depression in rats. Volinanserin also reversed ICSS depression by mescaline, but it was only partially effective to reduce the effects of psilocybin, and it exacerbated ICSS depression by salvinorin A. CONCLUSION: Although hallucination-related HTR behavior induced by phenethylamine, ergoline, and tryptamine psychedelics appears to be 5-HT2AR-mediated, the receptor(s) responsible for behavioral disruptive effects may differ among these three structural classes.
BACKGROUND: Clinical studies suggest that psychedelics exert robust therapeutic benefits in a number of psychiatric conditions including substance use disorder. Preclinical studies focused on safety and efficacy of these compounds are necessary to determine the full range of psychedelics' effects. OBJECTIVES: The present study explores the behavioral pharmacology of structurally distinct psychedelics in paradigms associated with serotonin 2A receptor (5-HT2AR) activation and behavioral disruption in two rodent models. Utilizing the selective 5-HT2AR antagonist volinanserin, we aimed to provide further pharmacological assessment of psychedelic effects in rodents. METHODS: We compared volinanserin (0.0001-0.1 mg/kg) antagonism of the phenethylamine 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI, 1.0 mg/kg) and the ergoline lysergic acid diethylamide (LSD, 0.32 mg/kg) in preclinical assays predictive of hallucinations (head-twitch response or HTR in mice) and behavioral disruption (intracranial self-stimulation or ICSS in rats). Volinanserin antagonism of the phenethylamine mescaline, the tryptamine psilocybin, and the k-opioid receptor agonist salvinorin A was also evaluated in the rat ICSS assay. RESULTS: Volinanserin had similar potency, effectiveness, and time-course to attenuate DOI-induced HTR in mice and ICSS depression in rats. Volinanserin completely blocked LSD-induced HTR in mice, but not LSD-induced ICSS depression in rats. Volinanserin also reversed ICSS depression by mescaline, but it was only partially effective to reduce the effects of psilocybin, and it exacerbated ICSS depression by salvinorin A. CONCLUSION: Although hallucination-related HTR behavior induced by phenethylamine, ergoline, and tryptamine psychedelics appears to be 5-HT2AR-mediated, the receptor(s) responsible for behavioral disruptive effects may differ among these three structural classes.
Authors: Rachel A Davies; Tyson R Baird; Vy T Nguyen; Brian Ruiz; Farhana Sakloth; Jose M Eltit; S Stevens Negus; Richard A Glennon Journal: ACS Chem Neurosci Date: 2020-05-27 Impact factor: 4.418
Authors: Dasiel O Borroto-Escuela; Wilber Romero-Fernandez; Manuel Narvaez; Julia Oflijan; Luigi F Agnati; Kjell Fuxe Journal: Biochem Biophys Res Commun Date: 2013-12-02 Impact factor: 3.575
Authors: Robin Carhart-Harris; Bruna Giribaldi; Rosalind Watts; Michelle Baker-Jones; Ashleigh Murphy-Beiner; Roberta Murphy; Jonny Martell; Allan Blemings; David Erritzoe; David J Nutt Journal: N Engl J Med Date: 2021-04-15 Impact factor: 91.245
Authors: Michael P Bogenschutz; Alyssa A Forcehimes; Jessica A Pommy; Claire E Wilcox; P C R Barbosa; Rick J Strassman Journal: J Psychopharmacol Date: 2015-01-13 Impact factor: 4.153
Authors: Cécile Béguin; David N Potter; Jennifer A Dinieri; Thomas A Munro; Michele R Richards; Tracie A Paine; Loren Berry; Zhiyang Zhao; Bryan L Roth; Wei Xu; Lee-Yuan Liu-Chen; William A Carlezon; Bruce M Cohen Journal: J Pharmacol Exp Ther Date: 2007-10-19 Impact factor: 4.030
Authors: Lindsay P Cameron; Robert J Tombari; Ju Lu; Alexander J Pell; Zefan Q Hurley; Yann Ehinger; Maxemiliano V Vargas; Matthew N McCarroll; Jack C Taylor; Douglas Myers-Turnbull; Taohui Liu; Bianca Yaghoobi; Lauren J Laskowski; Emilie I Anderson; Guoliang Zhang; Jayashri Viswanathan; Brandon M Brown; Michelle Tjia; Lee E Dunlap; Zachary T Rabow; Oliver Fiehn; Heike Wulff; John D McCorvy; Pamela J Lein; David Kokel; Dorit Ron; Jamie Peters; Yi Zuo; David E Olson Journal: Nature Date: 2020-12-09 Impact factor: 49.962
Authors: Mario de la Fuente Revenga; Bohan Zhu; Christopher A Guevara; Lynette B Naler; Justin M Saunders; Zirui Zhou; Rudy Toneatti; Salvador Sierra; Jennifer T Wolstenholme; Patrick M Beardsley; George W Huntley; Chang Lu; Javier González-Maeso Journal: Cell Rep Date: 2021-10-19 Impact factor: 9.423
Authors: Robin L Carhart-Harris; Mark Bolstridge; James Rucker; Camilla M J Day; David Erritzoe; Mendel Kaelen; Michael Bloomfield; James A Rickard; Ben Forbes; Amanda Feilding; David Taylor; Steve Pilling; Valerie H Curran; David J Nutt Journal: Lancet Psychiatry Date: 2016-05-17 Impact factor: 27.083